Statera Biopharma Valuation
| STABDelisted Stock | USD 0.04 0.0003 0.82% |
Statera Biopharma seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Statera Biopharma from inspecting the company fundamentals such as Shares Owned By Insiders of 15.93 %, return on equity of -2.87, and Current Valuation of 12.92 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Statera Biopharma's price fluctuation is not too volatile at this time. Calculation of the real value of Statera Biopharma is based on 3 months time horizon. Increasing Statera Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Statera Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Statera Pink Sheet. However, Statera Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0361 | Real 0.0343 | Hype 0.04 | Naive 0.0561 |
The real value of Statera Pink Sheet, also known as its intrinsic value, is the underlying worth of Statera Biopharma Company, which is reflected in its stock price. It is based on Statera Biopharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Statera Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Statera Biopharma helps investors to forecast how Statera pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Statera Biopharma more accurately as focusing exclusively on Statera Biopharma's fundamentals will not take into account other important factors: Statera Biopharma Total Value Analysis
Statera Biopharma is at this time forecasted to have valuation of 12.92 M with market capitalization of 1.97 M, debt of 10.62 M, and cash on hands of 506.1 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Statera Biopharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.92 M | 1.97 M | 10.62 M | 506.1 K |
Statera Biopharma Investor Information
About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.16. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Statera Biopharma recorded a loss per share of 0.76. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 28th of January 2015. Based on the key measurements obtained from Statera Biopharma's financial statements, Statera Biopharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Statera Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Statera Biopharma has an asset utilization ratio of 7.02 percent. This suggests that the Company is making $0.0702 for each dollar of assets. An increasing asset utilization means that Statera Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Statera Biopharma Ownership Allocation
Statera Biopharma shows a total of 54.66 Million outstanding shares. Statera Biopharma has 15.93 % of its outstanding shares held by insiders and 5.41 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Statera Biopharma Profitability Analysis
The company reported the previous year's revenue of 1.49 M. Net Loss for the year was (101.88 M) with profit before overhead, payroll, taxes, and interest of 998.72 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Statera Biopharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Statera Biopharma and how it compares across the competition.
About Statera Biopharma Valuation
The pink sheet valuation mechanism determines Statera Biopharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Statera Biopharma. We calculate exposure to Statera Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Statera Biopharma's related companies.Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropeniaanemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the bodys immune system and restore homeostasis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.
8 Steps to conduct Statera Biopharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Statera Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Statera Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Statera Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Statera Biopharma's revenue streams: Identify Statera Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Statera Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Statera Biopharma's growth potential: Evaluate Statera Biopharma's management, business model, and growth potential.
- Determine Statera Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Statera Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Statera Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 35.1 M | |
| Retained Earnings | -129.5 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |